The content on this site is intended for healthcare professionals only
Significance of gut microbiota in patients receiving CAR T cell immunotherapy
Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA
17 Dec 2021
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal...
Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India
21 Sep 2021
KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resecte...
Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA
18 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
17 Sep 2021
Vaccinations in myeloma patients including for COVID-19
Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria
31 Aug 2021
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
22 Jun 2021
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma
Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA
9 Jun 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
8 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
8 Jun 2021
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
4 Jun 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
16 Apr 2021